248 related articles for article (PubMed ID: 28838417)
1. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
Shivashankar R; Pardi DS
Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
[TBL] [Abstract][Full Text] [Related]
2. [Vedolizumab in the treatment of Crohn's disease].
Gisbert JP; Domènech E
Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
[TBL] [Abstract][Full Text] [Related]
3. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
4. Experience With Anti-TNF-α Biologic Agents in Succession in Patients With Crohn's Disease: A Retrospective Analysis of a Single Center.
Ferges W; Rampertab SD; Shafqet M; Salimi Q; You G; Yousefzadeh E; Cheng JQ; Das KM
J Clin Gastroenterol; 2016 Apr; 50(4):326-30. PubMed ID: 25984976
[TBL] [Abstract][Full Text] [Related]
5. Optimizing biological therapy in Crohn's disease.
Gecse KB; Végh Z; Lakatos PL
Expert Rev Gastroenterol Hepatol; 2016; 10(1):37-45. PubMed ID: 26471077
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
8. Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.
Hirten R; Longman RS; Bosworth BP; Steinlauf A; Scherl E
Am J Gastroenterol; 2015 Dec; 110(12):1737-8. PubMed ID: 26673509
[No Abstract] [Full Text] [Related]
9. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
11. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
Peyrin-Biroulet L
Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
[TBL] [Abstract][Full Text] [Related]
12. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
13. ACG Clinical Guideline: Management of Crohn's Disease in Adults.
Lichtenstein GR; Loftus EV; Isaacs KL; Regueiro MD; Gerson LB; Sands BE
Am J Gastroenterol; 2018 Apr; 113(4):481-517. PubMed ID: 29610508
[TBL] [Abstract][Full Text] [Related]
14. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
[TBL] [Abstract][Full Text] [Related]
15. Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis.
Ananthakrishnan AN; Hur C; Korzenik JR
Dig Dis Sci; 2012 Feb; 57(2):472-80. PubMed ID: 21909990
[TBL] [Abstract][Full Text] [Related]
16. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.
Singh S; Fumery M; Sandborn WJ; Murad MH
Aliment Pharmacol Ther; 2018 Aug; 48(4):394-409. PubMed ID: 29920733
[TBL] [Abstract][Full Text] [Related]
17. Managing perianal Crohn's fistula in the anti-TNFα era.
Tozer P; Borowski DW; Gupta A; Yassin N; Phillips R; Hart A
Tech Coloproctol; 2015 Nov; 19(11):673-8. PubMed ID: 26264168
[TBL] [Abstract][Full Text] [Related]
18. Real-world Experience of Anti-tumor Necrosis Factor Therapy for Internal Fistulas in Crohn's Disease: A Retrospective Multicenter Cohort Study.
Kobayashi T; Hishida A; Tanaka H; Nuki Y; Bamba S; Yamada A; Fujii T; Shinzaki S; Yokoyama Y; Yoshida A; Ozeki K; Ashizuka S; Kamata N; Nanjo S; Kakimoto K; Nakamura M; Matsui A; Yamauchi R; Takahashi S; Tomizawa T; Yoshino T; Hibi T
Inflamm Bowel Dis; 2017 Dec; 23(12):2245-2251. PubMed ID: 29084079
[TBL] [Abstract][Full Text] [Related]
19. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study.
Doecke JD; Hartnell F; Bampton P; Bell S; Mahy G; Grover Z; Lewindon P; Jones LV; Sewell K; Krishnaprasad K; Prosser R; Marr D; Fischer J; R Thomas G; Tehan JV; Ding NS; Cooke SE; Moss K; Sechi A; De Cruz P; Grafton R; Connor SJ; Lawrance IC; Gearry RB; Andrews JM; Radford-Smith GL;
Aliment Pharmacol Ther; 2017 Feb; 45(4):542-552. PubMed ID: 27995633
[TBL] [Abstract][Full Text] [Related]
20. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
